NFA
DOVA

Nationwide Fund Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Nationwide Fund Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,061
Closed -$50K – 2756
2017
Q3 		$50K Buy
+2,061
New +$48.9K ﹤0.01% 3042

Other funds holding DOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Nationwide Fund Advisors's DOVA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2017, closing a stake of 2,061 shares — an estimated $50K sold.

Nationwide Fund Advisors first reported a position in DOVA in Q3 2017 and held it in 1 quarter. The position peaked at $50K in Q3 2017. 48 funds tracked by Wall St. Rank hold DOVA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 2,061 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $50K.
  • Nationwide Fund Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.